Principal Financial Group Inc. Reduces Stock Position in Repligen Co. (NASDAQ:RGEN)

Principal Financial Group Inc. trimmed its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 30.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,991 shares of the biotechnology company's stock after selling 52,435 shares during the quarter. Principal Financial Group Inc. owned about 0.22% of Repligen worth $18,006,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Toronto Dominion Bank raised its stake in shares of Repligen by 1.5% in the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock worth $656,000 after acquiring an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock valued at $982,000 after purchasing an additional 89 shares in the last quarter. Ballentine Partners LLC grew its holdings in Repligen by 6.2% during the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock worth $269,000 after purchasing an additional 105 shares during the period. Diversified Trust Co increased its holdings in shares of Repligen by 3.7% in the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock valued at $372,000 after purchasing an additional 106 shares during the last quarter. Finally, CWM LLC lifted its holdings in Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 114 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares of the company's stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.20% of the stock is owned by corporate insiders.

Repligen Price Performance

NASDAQ:RGEN traded down $17.70 during trading hours on Friday, reaching $124.73. The stock had a trading volume of 1,915,115 shares, compared to its average volume of 665,967. The stock has a market capitalization of $6.99 billion, a PE ratio of -337.10, a PEG ratio of 4.36 and a beta of 0.96. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The company has a 50 day moving average price of $141.54 and a two-hundred day moving average price of $144.77.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the previous year, the firm earned $0.23 earnings per share. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Repligen Co. will post 1.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on RGEN. Wolfe Research assumed coverage on Repligen in a research report on Thursday. They issued a "peer perform" rating on the stock. Benchmark restated a "hold" rating on shares of Repligen in a report on Monday, August 5th. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a report on Wednesday. Wells Fargo & Company started coverage on Repligen in a report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.